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Abstract: Designs for biomarker validation have been proposed and
used in the phase III oncology clinical trial setting. Broadly, these
designs follow either an enrichment (i.e., targeted) strategy or an
all-comers (i.e., unselected) strategy. An enrichment design screens
patients for the presence or absence of a marker or a panel of
markers and then only includes patients who either have or do not
have a certain marker characteristic or profile. In contrast, all
patients meeting the eligibility criteria (regardless of a particular
biomarker status) are entered into an all-comers design. The strength
of the preliminary evidence, the prevalence of the marker, the
reproducibility and validity of the assay, and the feasibility of
real-time marker assessment play a major role in the choice of the
design. In this report, we discuss the parameters under which the
enrichment or an all-comers design strategy would be appropriate
for phase II trials.
Key Words: All-comers, Adaptive, Biomarker, Enrichment, Phase
II, Randomized.
(J Thorac Oncol. 2011;6: 658–660)
Phase I clinical trials are first-in-man studies that primarilyfocus on the safety profile of a regimen. With the devel-
opment of molecularly targeted therapies, vaccines, and im-
munotherapy, the focus of phase I trials is shifting toward the
identification of a biologically optimal dose, as these agents
typically have limited toxicity concerns but unknown dose-
efficacy relationships.1 Most phase I trials of targeted agents
include an expanded cohort of patients with a certain marker
profile at the recommended dose to understand the treatment
effects (efficacy or toxicity) within marker defined sub-
groups. An example is the testing of crizotinib in patients
with anaplastic lymphoma kinase (ALK) -positive non-small
cell lung cancer (NSCLC).2,3 An expanded cohort of patients
with ALK-positive tumors (82/1500 patients, 5% of pa-
tients who underwent screening) was enrolled into the phase
I trial. The observed response rate was 57% per the RECIST,
and disease control rate at 8 weeks was 87%. Based on these
data, this agent is currently being tested in a phase III setting
for patients with ALK-positive NSCLC. Such exceptional
results are, however, rare, and most agree to proceed to phase
II testing after completion of phase I.
Phase II clinical trials are designed primarily to identify
promising experimental therapies that can then be tested
further in a definitive phase III trial. Although there is a
wealth of literature on the types of phase II designs (single
arm, randomized, screening, selection, etc.)4 and under what
circumstances a particular design is valid, there is very little
published on the question of patient selection (i.e., biologic
subsetting) when evaluating molecularly targeted agents.
In this brief report, we first discuss the role of random-
ization and adaptive design strategies in the context of as-
sessing targeted therapies. Next, we review the concept of
enrichment (or targeted) and all-comers (or unselected) de-
signs in the setting of phase II trials and discuss the relevance
of each in light of the strength of the preliminary evidence,
the prevalence of the marker, reproducibility and validity of
the assay, and the feasibility of real-time marker assessment.
RANDOMIZATION AND ADAPTIVE DESIGN
STRATEGIES
Randomized phase II trials are critical in the current era
of constrained resources and availability of multiple promis-
ing therapies for a given disease. Changes in patient popula-
tions based on biologic subsetting, evolution in imaging
technologies, make comparison against historical controls
inaccurate. Moreover, randomized phase II designs are es-
sential for biomarker discovery, specifically for making the
distinction between a prognostic and predictive marker.4,5
Adaptive design strategies are a class of randomized phase II
designs by which a variety of marker signatures and drugs
can be tested. In these designs, the success of the drug-
biomarker subgroup is assessed on an ongoing manner, and in
some designs, the randomization ratio is altered and/or the
underperforming drugs and/or the biomarker subgroups
tested eliminated midway through the trial. The essential
requirements for these designs are (1) a rapid and reliable
endpoint, which is somewhat challenging as most oncology
trials use time to event endpoints or endpoints that involve
following a patient’s status for a predetermined time period
(such as the progression status at 2 years) and (2) real-time
access to data, which can be a daunting task in multicenter
trials.
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Two phase II trials that used an adaptive design strategy
are I-SPY 2 (investigation of serial studies to predict thera-
peutic response with imaging and molecular analysis 2) and
BATTLE (biomarker-integrated approaches of targeted ther-
apy for lung cancer elimination trial).6–8 I-SPY 2 is an
ongoing neoadjuvant trial in breast cancer that is designed to
compare the efficacy of standard therapy to the efficacy of
novel drugs in combination with chemotherapy. All drugs
will be evaluated against biomarker signatures; regimens that
have a high predictive probability of being effective will be
moved forward to phase III testing with their corresponding
biomarker signature(s). Regimens that have a low probability
of efficacy for all biomarker signatures will be dropped from
further development.6 BATTLE used an outcome-based
adaptive randomization design for randomizing patients to
treatment choices based on multiple biomarker profiles in
NSCLC. Patients had their tumors tested for 11 different
biomarkers and were subsequently randomized to one of four
treatment choices. The first 97 patients enrolled to the trial
were randomly assigned to one of the four treatments equally,
and subsequently, new patients were adaptively randomized.
The preliminary results from BATLLE are promising,
wherein, as hypothesized, each drug was found to work best
for patients with a specific molecular profile.7,8 Two succes-
sor trials, BATTLE 2 and BATTLE 3, are currently in
development.
ENRICHMENT VERSUS ALL-COMERS DESIGNS
An enrichment design screens patients for the presence
or absence of a marker or a panel of markers and then only
includes patients in the clinical trial who either have or do not
have a certain marker characteristic or profile.9 This results in
a stratification of the study population, with a goal of under-
standing the safety, tolerability, and clinical benefit of a
treatment in the subgroup of the patient population defined by
a specific marker status. This design is based on the paradigm
that not all patients will benefit from the study treatment
under consideration but rather that the benefit will be re-
stricted to a subgroup of patients who either express or do not
express a specific molecular feature. In an all-comers design,
all patients meeting the eligibility criteria, which does not
include a specific status on the biomarker in question, are
entered.5 The ability to provide adequate tissue may be an
eligibility criterion for these designs but not the specific
biomarker result or the status of a biomarker characteristic.
The need to collect upfront tissue and blood specimens is
critical in the current era of targeted therapies to match the
right patient to the right drug.10
Table 1 lists some general criteria to consider when
deciding between enrichment versus all-comers design in a
phase II setting. Enrichment designs are clearly appropriate
when the marker prevalence is low (15–20%), whereby it is
not feasible to include all patients regardless of the marker
status as the treatment effect in the overall population will be
diluted. In this case, an all-comers trial design would require
a prohibitively large sample size. When the marker preva-
lence is high (50%), the assay performance is not well
established (no established cutpoint for marker status defini-
tion, laboratory is not Clinical Laboratory Improvement
Amendments certified, etc.), the turn around times for marker
assessment are long (more than a week, for example, in
second- or third-line treatment settings), and the preliminary
evidence is unclear, an all-comers design is appropriate. In
most instances, however, an all-comers design should clearly
incorporate a prospectively specified subgroup analyses for
retrospective assessment of the treatment effect within bio-
marker-defined subgroups. This is critical to ensure that the
effect of the drug is tested both on the overall and prospec-
tively defined subsets of patients so as to not incorrectly
conclude that the drug is not effective, when it may be
effective for a smaller subset of the population.
In cases where the prevalence of the marker in question
is moderate (between 20% and 50%), then a possible strategy
could be as follows:
1. Perform a single-arm enrichment trial (pilot) as a proof of
concept that the treatment likely has a major effect within
a marker subgroup.
2. Perform an unselected phase II (randomized) trial, either.
a. Stratified by marker status, with a primary hypothesis
within the marker subgroup hypothesized to derive the
most benefit based on the pilot trial in step 1, but





Strongly suggest benefit in marker-defined subgroups Yes —
Uncertain about benefit in overall population vs. marker-defined subgroups — Yes
Assay reproducibility and validity
Excellent (high concordance between local and central testing,




Rapid (2–3 days; without causing delay in the start of therapy) Yes Yes
Slow to modest (1 week or more) — Yes (retrospective marker
subgroup assessment)
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sufficient patients to potentially demonstrate lack of
benefit in the other subgroup(s).
b. Adaptive design by evaluating success in an ongoing
manner within the marker subgroups.
In summary, enrichment designs are appropriate when
one or more of the following are likely:
1. The treatment in question has modest absolute benefit in
the unselected population but can cause significant
toxicity.
2. In the absence of selection, therapeutic results are sim-
ilar whereby an enrichment design (even if incorrect)
would not hurt.
3. There is compelling preliminary evidence to suggest
that patients with or without that marker profile do not
benefit from the treatments in question, thus including
all patients regardless of the marker profile is ethically
not possible.
4. Assay reproducibility and accuracy is well established,
for example, a high degree of concordance between
local and central laboratory testing.
5. Rapid turnaround time for marker assessment is avail-
able, so as to not delay treatment initiation.
SUMMARY
Stewart et al.11 demonstrated through well-conducted
simulation studies the impact of subpopulation characteristics
on overall study outcomes. One of their main conclusions is
that although molecular profiling is expensive, not doing so is
ultimately far more expensive and gives the wrong answer.
Clearly, biomarker identification is critical to future ongoing
oncology drug development. In the setting of phase II trials,
when the mechanism of action of a targeted agent is known
(i.e., the target is known, and it is well established that the
agent under investigation selectively inhibits or activates the
target), then clinical trials with an enrichment strategy are
appropriate, such that large gains can be expected in a subset
of patients. On the other hand, an all-comers design is optimal
where preliminary evidence regarding the treatment benefit
and/or the assay performance characteristics is uncertain, to
allow a more comprehensive assessment of a new agent’s
potential activity.
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